Angion to Participate in Upcoming Investment Conference

Rhea-AI Summary

Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 3:20 PM Eastern Time. The event will be led by Stifel Managing Director Annabel Samimy. A webcast will be available on Angion's investor relations page and archived for 30 days. Angion focuses on developing treatments for acute organ injuries and fibrotic diseases, with ongoing trials for its lead candidates, ANG-3777 for acute kidney injury and ANG-3070 for fibrotic disease.

UNIONDALE, N.Y., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today announced its management team will participate in a fireside chat with Stifel Managing Director and Senior Analyst Annabel Samimy at the Stifel 2021 Virtual Healthcare Conference.

Details are as follows:

Event: Stifel 2021 Virtual Healthcare Conference
Date: Monday, November 15^th
Time: 3:20pm Eastern US Time

A webcast of the fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir.angion.com/events-presentations. The webcast will remain archived on Angion’s website for approximately 30 days.

About Angion
Angion is committed to transforming the treatment paradigm for patients suffering from acute organ injuries and fibrotic diseases for which there are no approved medicines or where existing approved medicines have limitations. Angion’s lead product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic. An exploratory Phase 2 trial of ANG-3777 for the treatment of acute kidney injury associated with cardiac surgery involving cardiopulmonary bypass surgery is ongoing with data expected in the fourth quarter of 2021. Angion is scheduled to begin a Phase 2 trial evaluating ANG-3070, an oral tyrosine kinase receptor inhibitor for the treatment of fibrotic disease, in patients with primary proteinuric kidney diseases. Additionally, Angion has preclinical programs for a rho kinase 2 (ROCK2) inhibitor and a CYP11B2 (aldosterone synthase) inhibitor. For more information, please visit www.angion.com.

Contact
Daniel Ferry
LifeSci Advisors
617-430-7576
daniel@lifesciadvisors.com

FAQ

What is Angion Biomedica's upcoming event in November 2021?

Angion Biomedica will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021.

What time will Angion's management team present at the Stifel Conference?

Angion's management will present at 3:20 PM Eastern Time on November 15, 2021.

How can I access the webcast of Angion's fireside chat?

The webcast can be accessed through the events and presentations page on Angion's investor relations website.

What are the main products Angion Biomedica is developing?

Angion is developing ANG-3777 for acute kidney injury and ANG-3070 for fibrotic disease.

When is data expected for ANG-3777's ongoing trial?

Data for ANG-3777's trial is expected in the fourth quarter of 2021.